Randomized, Double-blind, Placebo-controlled Study to Evaluate Safety, Mechanistic Effects, and Effects on Disease Activity of MH002 in Subjects with Mild to Moderate Ulcerative Colitis: A First-in-human Study
Latest Information Update: 04 Mar 2025
At a glance
- Drugs MH 002 (Primary)
- Indications Ulcerative colitis
- Focus Adverse reactions; First in man
- Sponsors MRM Health
Most Recent Events
- 15 May 2024 Results presented in the MRM Health Media Release.
- 15 May 2024 According to a MRM Health media release, data from this study will be presented oral presentations during the 2024 Digestive Disease Week (DDW) meeting, being held May 18-21, 2024 in Washington, D.C. at the Walter E. Washington Convention Center.
- 19 Sep 2023 According to MRM Health Media Release, full analysis and presentation of the data from this trial expected by end 2023